Using immunoreactivity scores (IRS), calculated by multiplying positivity and intensity scores, we categorized the samples into two groups: high MCT1 expression (IRS ≥ 4, n=36, 76.6%) and low MCT1 expression (IRS < 4, n=11, 23.4%) in RB tumors (Fig. 7A). The gene discussed is SLC16A1; the disease is retinoblastoma.